Table 2 Demographic, laboratory, clinical data, and treatment outcomes between severe and mild to moderate patients
| Â | Severe | Mild to moderate | P value | |
|---|---|---|---|---|
n = 34 | n = 48 | |||
Demographics | Age, median months (IQR) | 2 (1, 4) | 5 (2, 16) | 0.004 |
Gender (male) | 20 (59%) | 29 (60%) | 0.885 | |
Clinical features | Underlying diseases | 15 (44%) | 10 (21%) | 0.024 |
Peak fever (℃) | 37.3 (37, 38.6) | 38.2 (37, 39) | 0.033 | |
Febrile duration | 0 (0, 2) | 1 (0, 4) | 0.018 | |
Laboratory testing results | WBC (10^9/L) | 8.4 (6.8, 11.7) | 9.9 (7.0, 12.7) | 0.423 |
Neutrophil% | 31 (21, 59) | 36 (22, 49) | 0.826 | |
Lymphocyte% | 57 (34, 65) | 56 (37, 65) | 0.872 | |
Monocyte% | 9 (5, 10) | 8 (7, 9) | 0.856 | |
CRP (mg/L) | 1 (1, 10.6) | 1 (1, 6.8) | 0.685 | |
CD4 + cell% | 37 (36, 38) | 37 (35, 41) | 0.603 | |
CD8 + cell% | 20 (17, 21) | 20 (16, 23) | 0.817 | |
CD19 + cell% | 36 (31, 40) | 26 (34, 37) | 0.097 | |
DNT cell% | 2 (1.0, 3.0) | 2.4 (1.9, 3.0) | 0.038 | |
CK (U/L) | 98 (65, 132) | 85 (68, 118) | 0.944 | |
CK-MB (ug/L) | 4.1 (2.4, 7.9) | 2.9 (1.7, 4.7) | 0.057 | |
LDH (U/L) | 285 (259, 381) | 303 (256, 330) | 0.936 | |
HBDH (U/L) | 231 (208, 298) | 248 (219, 269) | 0.675 | |
Outcomes | Extrapulmonary complications | 19 (56%) | 14 (29%) | 0.015 |
Hospital stay | 8 (7,11) | 7 (6,8) | 0.016 | |
PICU admission | 32 (94%) | 12 (25%) | < 0.001 | |
PICU stay | 1 (1,2) | 0 (0,1) | < 0.001 | |
Death | 3 (9%) | 0 | 0.134 | |